8-K: Keros Therapeutics Updates Pipeline with Promising Clinical Data and New Obesity Program

Keros Therapeutics provides an update on its clinical programs for KER-050, KER-012, and KER-065, highlighting positive results and future milestones.

Summary

• Keros Therapeutics is a clinical-stage biopharmaceutical company focused on transforming growth factor-beta (TGF-) signaling.
• The company's lead product candidate, KER-050, is being evaluated for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes (MDS) and myelofibrosis (MF).
• In an ongoing Phase 2 trial for MDS, KER-050 showed a 50% overall response rate in the modified intent-to-treat population, with 45.5% of high transfusion burden patients responding.
• Transfusion independence was achieved by 39.1% of patients at 8 weeks, with durable responses observed up to 24 weeks.
• Patients with baseline erythropoietin (EPO) levels below 500 U/L showed higher response rates, with 56% overall response.
• KER-050 also demonstrated improvements in FACIT-Fatigue scores in transfusion-independent responders, indicating improved quality of life.
• Exploratory analysis suggests KER-050 may reduce cardiac stress, as indicated by decreases in NT-proBNP levels.
• In a Phase 2 trial for MF, KER-050 showed potential to address multiple aspects of the disease, including improvements in erythropoiesis, spleen size, and symptoms.
• KER-012, another product candidate, is being developed for pulmonary arterial hypertension (PAH) and cardiovascular disorders.
• Preclinical data for KER-012 showed reductions in pulmonary arterial pressure, right ventricle hypertrophy, and cardiac fibrosis in rodent models.
• A Phase 2 trial for PAH is ongoing, and an open-label biomarker trial in chronic heart failure patients is also underway, with initial data expected in the second half of 2024.
• KER-065, a novel activin receptor ligand trap, is being developed for obesity and neuromuscular disorders.
• Preclinical studies of KER-065 showed increases in muscle mass and decreases in fat mass, both as a monotherapy and in combination with GLP-1 receptor agonists.
• A Phase 1 trial for KER-065 in healthy volunteers is underway, with data expected in Q1 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data for multiple product candidates, particularly KER-050 in MDS and KER-065 in obesity. The preclinical data for KER-012 is also encouraging. While there are risks associated with drug development, the overall tone is optimistic and suggests potential for future growth.

Positives

• KER-050 demonstrated a strong overall response rate of 50% in MDS patients, indicating its potential as an effective treatment.
• The durable transfusion independence observed with KER-050 suggests a long-lasting benefit for MDS patients.
• The higher response rates in patients with lower EPO levels suggest a specific patient population that may benefit most from KER-050.
• The improvements in fatigue scores with KER-050 highlight its potential to improve the quality of life for MDS patients.
• The observed reduction in NT-proBNP levels suggests a potential benefit of KER-050 in reducing cardiac stress.
• KER-050 showed promising results in MF, with improvements in erythropoiesis, spleen size, and symptoms.
• KER-012 demonstrated significant reductions in pulmonary arterial pressure and cardiac fibrosis in preclinical models, indicating its potential for treating PAH.
• KER-065 showed significant increases in muscle mass and decreases in fat mass in preclinical studies, suggesting its potential for treating obesity and neuromuscular disorders.
• The combination of KER-065 with GLP-1 agonists showed synergistic effects in reducing fat mass, indicating a potential for enhanced weight loss.
• Keros has a proprietary discovery approach that has generated a pipeline of ActRII ligand traps, suggesting potential for future product candidates.

Negatives

• Some patients experienced treatment-related adverse events with KER-050, including injection site reactions, dyspnea, and syncope.
• Two patients in the KER-050 MDS trial experienced fatal treatment-emergent serious adverse events, although these were assessed as unrelated to the study treatment.
• The maximum dose of sotatercept in PAH was limited due to increased hemoglobin, which may be a concern for similar therapies.
• GLP-1 receptor agonists can lead to a loss of lean muscle mass, which KER-065 aims to address, but this is still a challenge in the obesity treatment landscape.
• Weight loss achieved with GLP-1 RAs is often regained after stopping treatment, highlighting the need for long-term solutions.

Risks

• Keros has a limited operating history and has incurred historical losses.
• The company's ability to raise additional funding is crucial for completing the development and commercialization of its product candidates.
• Keros is highly dependent on the success of its product candidates, KER-050, KER-012, and KER-065.
• There is a risk of delays in initiating, enrolling, or completing clinical trials.
• Keros faces competition from third parties developing products for similar uses.
• The company's ability to obtain, maintain, and protect its intellectual property is critical.
• Keros is dependent on third parties for manufacturing, clinical trials, and preclinical studies.

Future Outlook

Keros anticipates several key milestones, including engaging with regulators on the design of a Phase 3 MDS trial, announcing additional data from ongoing Phase 2 trials for MDS and MF, providing updates on the Phase 2 PAH trial, and announcing initial data from the Phase 2 heart failure trial and the Phase 1 obesity trial.

Management Comments

• Keros believes its product candidates have the potential to unlock the full therapeutic benefits of modulating the TGFsuperfamily.
• Keros is focused on transforming the lives of a wide range of patients with disorders linked to dysfunctional TGFsuperfamily signaling.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on TGFsuperfamily signaling. The results of Keros' clinical trials are being closely watched by investors and competitors in the fields of hematology, pulmonary hypertension, and obesity. The development of novel therapies for these conditions is a significant area of research and investment.

Comparison to Industry Standards

• The 50% overall response rate in the KER-050 MDS trial is competitive with other treatments in the space, such as Reblozyl, which showed a 20% response rate in high transfusion burden patients in a second-line setting.
• The durable transfusion independence observed with KER-050 is a positive sign, as many current treatments for MDS have limited long-term efficacy.
• The preclinical data for KER-012 in PAH is consistent with the results seen with sotatercept, a third-party therapy that has shown the importance of the TGFsuperfamily in PAH.
• The preclinical data for KER-065 in obesity is promising, as it addresses the issue of lean muscle loss associated with GLP-1 agonists, a common problem in the obesity treatment landscape. Bimagrumab, an ActRIIA/ActRIIB antibody, has shown similar increases in muscle mass, but KER-065 is designed for subcutaneous administration, which may be more convenient for patients.
• The combination of KER-065 with GLP-1 agonists is a novel approach that could potentially lead to more effective weight loss treatments.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising clinical data and potential for future growth.
• Employees may be motivated by the progress of the company's clinical programs.
• Patients with MDS, MF, PAH, obesity, and neuromuscular disorders may benefit from the development of new treatment options.
• Suppliers and creditors may see increased business opportunities as the company progresses.

Next Steps

• Keros will engage with regulators on the design of a Phase 3 MDS trial for KER-050.
• Keros will continue to enroll patients in the Phase 2 PAH TROPOS trial for KER-012.
• Keros will continue to evaluate KER-012 in an open-label biomarker trial in patients with chronic heart failure.
• Keros will continue to evaluate KER-065 in a Phase 1 clinical trial in healthy volunteers.
• Keros will announce additional data from ongoing clinical trials in the coming quarters.

Key Dates

Keywords

KER-050, KER-012, KER-065, Myelodysplastic Syndromes, Myelofibrosis, Pulmonary Arterial Hypertension, Obesity, TGFsuperfamily, Activin A, Myostatin, Clinical Trials, Biopharmaceutical, Hematopoiesis, Muscle Mass, Fat Mass